NCT06867796View on ClinicalTrials.gov

A Safety and Pharmacokinetics Study of TL-001 in Healthy Adults

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Healthy Volunteers

Interventions

DRUG

TL-001

Intravenously administered

DRUG

Placebo

Intravenously administered

All Listed Sponsors

collaborator

Tigermed Australia Pty Ltd

UNKNOWN

lead

TrueLab Biopharmaceutical Co., Ltd

INDUSTRY